Otolaryngology: Open Access
ISSN: 2161-119X
Glenn, Otolaryngol (Sunnyvale) 2024, 14:4
Mini Review
Open Access

Capability of Brain Mast Cells for Therapeutic use in Immune Response to Bacterial and Viral Infections

Glenn Govender*

Catalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban, South Africa

Abstract

Mast cells, traditionally known for their role in allergic responses, are increasingly recognized for their involvement in immune modulation and host defense beyond allergic reactions. This review explores the emerging understanding of brain mast cells (BMCs) and their potential therapeutic applications in combating bacterial and viral infections. BMCs, located in the central nervous system (CNS), possess unique immunological properties that influence neuroinflammation and host defense mechanisms. Recent studies indicate BMCs' ability to respond to pathogens directly and modulate immune responses in infectious diseases. Understanding BMCs' capabilities and harnessing their therapeutic potential could lead to novel strategies for treating infections affecting the CNS and beyond.

Keywords: Brain mast cells; Neuroimmunology; CNS infections; Bacterial infections; Viral infections; Immune modulation; Therapeutic targets

Introduction

Mast cells are tissue-resident immune cells primarily known for their roles in allergic reactions and inflammation. Traditionally studied in peripheral tissues, recent research has identified mast cells within the brain, termed brain mast cells (BMCs). BMCs are strategically positioned within the blood-brain barrier (BBB) and the meninges, suggesting they play crucial roles in neuroinflammation and neuroimmune responses [1]. While BMCs' roles in neurodegenerative diseases and neuroinflammatory conditions have been explored, their potential in responding to bacterial and viral infections in the brain remains an area of active investigation. BMCs are equipped with receptors for various pathogens and immune mediators, allowing them to sense and respond to infectious agents within the CNS [2]. Upon activation, BMCs release a spectrum of cytokines, chemokines, and other immune modulators that can shape local immune responses. This capacity is critical for initiating and regulating neuroinflammation in response to infections [3]. Studies suggest that BMCs play a dual role in both promoting immune defense and contributing to pathological processes in CNS infections, depending on the context and the specific pathogen involved [4]. In bacterial infections such as meningitis or encephalitis, BMCs are activated by bacterial components or cytokines released by infected cells [5]. Activation triggers BMCs to release pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β, which recruit and activate microglia and other immune cells to clear the infection. Additionally, BMCs can release antimicrobial peptides and proteases that directly target pathogens, enhancing the local immune response [6]. In viral infections, BMCs respond to viral particles and nucleic acids, contributing to antiviral immunity through interferon production and activation of adaptive immune responses within the CNS. Harnessing BMCs' immunomodulatory capabilities holds promise for developing novel therapeutic strategies against CNS infections [7]. Approaches could include enhancing BMC activation to bolster immune responses in cases of immunodeficiency or dampening BMC activation to mitigate neuroinflammation and tissue damage in conditions like viral encephalitis or autoimmune disorders affecting the CNS [8]. Targeted modulation of BMC responses could also be explored to improve outcomes in bacterial meningitis or neuroinvasive viral infections where traditional treatments have limitations.

Challenges and future directions

Despite their potential, several challenges exist in harnessing BMCs for therapeutic use. These include understanding the precise roles of BMCs in different CNS infections, optimizing methods for targeting BMCs without compromising BBB integrity, and ensuring safety in manipulating neuroimmune responses. Future research should focus on elucidating BMCs' specific contributions to CNS immunity, exploring novel delivery methods for BMC-targeted therapies, and conducting preclinical and clinical trials to evaluate the efficacy and safety of BMC-based treatments in infectious diseases affecting the brain [9-12].

Conclusion

Brain mast cells represent a novel frontier in neuroimmunology, offering unique opportunities for therapeutic intervention in bacterial and viral infections of the CNS. Their ability to sense pathogens, modulate local immune responses, and interact with neural cells underscores their potential as therapeutic targets. Further research into BMC biology and their precise roles in infection control is essential for realizing the therapeutic promise of these intriguing immune cells.

Acknowledgement

None

Conflict of Interest

None

References

1. Sehgal IS, Dhooria S, Agarwal R (2017) chronic obstructive pulmonary disease and malnutrition in developing countries. Curr Opin Pulm Med 23: 139-148.

***Corresponding author:** Glenn Govender, Catalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban, South Africa, E-mail: glenn154@gmail.com

Received: 01-July-2024, Manuscript No: ocr-24-142554, **Editor assigned:** 03-July-2024, Pre-QC No: ocr-24-142554 (PQ), **Reviewed:** 17-July-2024, QC No: ocr-24-142554, **Revised:** 22-July-2024, Manuscript No: ocr-24-142554 (R), **Published:** 30-July-2024, DOI: 10.4172/2161-119X.1000585

Citation: Glenn G (2024) Capability of Brain Mast Cells for Therapeutic use in Immune Response to Bacterial and Viral Infections. Otolaryngol (Sunnyvale) 14: 585.

2. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347–365.
3. Choudhury G, Rabinovich R, MacNee W (2014) Comorbidities and systemic effects of chronic obstructive pulmonary disease. Clin Chest Med 35: 101-130.
4. Itoh M, Tsuji T, Nemoto K, Nakamura H, Nakamura H, et al. (2013) Undernutrition in patients with COPD and its treatment. Nutrients 5: 1316–1335.
5. Girón R, Matesanz C, García-Río F, Santiago ED, Mancha A, et al. (2009) Nutritional state during COPD exacerbation: Clinical and prognostic implications. Ann Nutr Metab 54: 52-58.
6. Gupta B, Kant S, Mishra R, Verma S (2010) Nutritional status of chronic obstructive pulmonary disease patients admitted in hospital with acute exacerbation. J Clin Med Res 2: 68-74.
7. Hoong JM, Ferguson M, Hukins C, Collins PF (2017) Economic and operational burden associated with malnutrition in chronic obstructive pulmonary disease. Clin Nutr 36: 1105–1109.
8. Hallin R, Gudmundsson G, Ulrik CS, Nieminen MM, Gislason T, et al. (2007) Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med 101: 1954-1960.
9. Ukleja A, Gilbert K, Mogensen KM, Walker R, Ward CT, et al. (2018) Standards for Nutrition Support: Adult Hospitalized Patients. Nutr Clin Pract 33: 906–920.
10. Ferguson M, Capra S, Bauer J, Banks M (1999) Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. Nutrition 15: 458–464.
11. Kruizenga HM, Seidell JC, De-Vet HCW, Wierdsma NJ, van Bokhorst-de van der Schueren MAE (2005) Development and validation of a hospital screening tool for malnutrition: the short nutritional assessment questionnaire (SNAQ). Clin Nutr 24: 75–82.
12. Stratton RJ, Hackston A, Longmore D, Dixon R, Price S, et al. (2004) Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the “malnutrition universal screening tool” ('MUST') for adults. Br J Nutr 92: 799–808.